CA-SIRIUS-THERAPEUTICS
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grid Dynamics Signs Strategic Collaboration Agreement with AWS to Advance Data Foundations for Generative AI9.12.2025 15:15:00 CET | Press release
Key Takeaways: Grid Dynamics has signed a multi-year agreement with Amazon Web Services (AWS) to accelerate AI-related services for enterprise customers. The agreement extends a 15-year collaboration and provides Grid Dynamics access to the AWS Data Foundations for Generative AI Program designed to help enterprises adopt and scale AI-enabled solutions. Through this expanded collaboration, Grid Dynamics is set to empower clients across every stage of their AI journey with modern, scalable, and secure data foundations from AWS. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a premier IT consulting and digital services provider, today announced it has entered into a multi-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS). The agreement focuses on enabling and scaling generative AI journeys for enterprise companies, extending a 15-year relationship between the companies. The collaboration provides Grid Dynamics access to the AWS Data Foundations for
Indero Named Best Employer by Mercer9.12.2025 15:00:00 CET | Press release
Indero, a global CRO specializing in dermatology and rheumatology, has been honored by Mercer, recognizing its excellence as a Best Employer. Indero is proud of its long-term commitment to building a workplace culture defined by trust, fairness, and meaningful employee experiences and believes this distinction reflects its positive impact in 2025. The Best Employers in Canada – Powered by Mercer certification program recognizes organizations that consistently deliver a positive and engaging employee experience, based on employee feedback. The degree of employee engagement is a crucial factor for both current and prospective clients and partners, since motivated and committed employees are more likely to excel in their roles and ensure the highest standards in the organization’s products and services. Formerly known as the Kincentric Best Employers, the program has highlighted Canada’s top workplaces for over 25 years and now benefits from Mercer’s expanded global reach and one of the m
Gulf Oil Selects DataXstream’s OMS+ Portal to Power LATAM Digital Transformation9.12.2025 14:33:00 CET | Press release
New deployment will enable Gulf Oil to modernize the distributor experience, support long-term digital growth and deliver a unified customer experience on SAP S/4HANA DataXstream LLC, an SAP® Endorsed App partner developing innovative solutions for SAP sales and distribution, today announced that Gulf Oil, a globally recognized lubricant company with operations in more than 25 countries, has selected OMS+ Portal to modernize and unify the company’s customer-facing sales platform across Latin America. The project is part of a broader initiative to streamline operations, enhance scalability and deliver a seamless buying experience that is fully integrated with SAP S/4HANA. As Gulf Oil continues its footprint across LATAM, the company needed a solution that would not only elevate the customer experience, but also provide the flexibility and performance needed to scale. OMS+ Portal will serve as the central platform for Gulf’s distributor network, offering a unified, SAP-embedded environme
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy9.12.2025 14:05:00 CET | Press release
Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer on-site liquid biopsy testing based on Guardant360® CDx technology. The collaboration expands access to precision oncology diagnostics and supports both routine care and clinical research. FPG 360 is one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. P
NTT DATA appoints CEO of newly established AI Company NTT DATA AIVista, Inc.9.12.2025 14:00:00 CET | Press release
Dr. Bratin Saha joins NTT DATA AIVista, Inc., bringing extensive experience in AI, infrastructure, platforms and solutions NTT DATA AIVista, Inc. established in Silicon Valley to help NTT operating companies accelerate the launch and scaling of AI native businesses NTT DATA, a global leader in AI, digital business and technology services, today announced the appointment of Dr. Bratin Saha as CEO of the newly established AI Company, NTT DATA AIVista, Inc., effective Dec 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209189202/en/ Dr. Bratin Saha, newly appointed CEO of NTT DATA AIVista, Inc. Saha brings deep expertise in AI, infrastructure, platforms and solutions; scaling new businesses and significant ecosystem relationships. Prior to joining NTT DATA, he held executive positions at NVIDIA, Amazon Web Services (AWS) and most recently DigitalOcean. At NVIDIA, Saha served as Vice President of Software Infrastructu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom